(Press-News.org) Contact information: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
High-dose cytarabine improves outcome in patients with AML in EORTC-GIMEMA AML-12 Trial
Results of the EORTC and GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto) AML-12 Trial appearing in the Journal of Clinical Oncology show that high-dose cytarabine in induction treatment improves outcome of adult patients with acute myeloid leukemia (AML). In particular, high-dose cytarabine produces higher remission and survival rates than the standard-dose cytarabine in patients younger than age 46 years old.
Dr. Roelof Willemze of the Leiden University Medical Centre and lead author of this report explains, "The most commonly administered induction regimen for patients with AML is a daily dose of 100 to 200 mg/m2 of cytarabine for seven to ten days in combination with three days of an anthracycline. This treatment has been shown to result in complete remission rates of 60% to 80% depending on age of the patient as well as genetic and molecular characteristics of the disease. Up until now, however, we did not have clear consensus on the benefit of higher dosages of cytarabine."
The AML-12 included 1,942 newly diagnosed patients with AML aged 15 to 60 years and compared remission induction treatment with daunorubicin, etoposide, and either standard-dose (100 mg/m2 per day by continuous infusion for 10 days) or high-dose (3,000 mg/m2 every 12 hours by 3-hour infusion on days 1, 3, 5, and 7) cytarabine. Patients in complete remission received a single consolidation cycle containing daunorubicin and intermediate dose cytarabine.
At a median follow-up of six years, overall survival was 38.7% for patients receiving standard-dose and 42.5% for those receiving high-dose cytarabine (log-rank test P = 0.06; multivariable analysis P = 0.009).
For patients younger than 46 years old, survival was 43.3% with standard-dose treatment and 51.9% with high-dose treatment (P = 0.009; multivariable analysis P = 0.003). Survival for patients 46 to 60 years old was 33.9% and 32.9%, respectively (P = 0.91).
Complete remission rates were 72.0% for standard-dose and 78.7% for high-dose (P < 0.001). Patients younger than 46 years old had complete remission rates of 75.6% and 82.4%, respectively, (P = 0.01), while patients 46 years and older had rates of 68.3% and 74.8%, respectively (P = 0.03).
###
The intergroup EORTC-GIMEMA AML-12 Trial was supported by an educational grant from the EORTC Charitable Trust and was conducted at 63 sites in ten countries: Austria, Belgium, Croatia, Czech Republic, France, Italy, Portugal, Slovakia, The Netherlands, and Turkey.
High-dose cytarabine improves outcome in patients with AML in EORTC-GIMEMA AML-12 Trial
2013-12-19
ELSE PRESS RELEASES FROM THIS DATE:
A new role for milk: Delivering polyphenols with anti-cancer activity
2013-12-19
A new role for milk: Delivering polyphenols with anti-cancer activity
Milk can serve as a protective carrier of bioactive molecules, suggests report in the Journal of Dairy Science®
Philadelphia, PA, December 19, 2013 – Polyphenols found in tea manifest anti-cancer ...
Corn pest decline may save farmers money
2013-12-19
Corn pest decline may save farmers money
Populations of European corn borer (ECB), a major corn crop pest , have declined significantly in the eastern United States, according to Penn State researchers. The decline suggests that the use of genetically modified, ECB-resistant corn ...
Breaking the cycle of obesity, inflammation and disease
2013-12-19
Breaking the cycle of obesity, inflammation and disease
ANN ARBOR—Researchers at University of Michigan have illuminated an aspect of how the metabolic system breaks down in obesity. The findings provide additional evidence that a drug entering clinical trials ...
Chewing gum is often the culprit for migraine headaches in teens
2013-12-19
Chewing gum is often the culprit for migraine headaches in teens
Tel Aviv University study finds that 87 percent of teens who quit chewing experience significant relief
Teenagers are notorious for chewing a lot of gum. The lip smacking, bubble popping, ...
African-American women must eat less or exercise more to lose as much weight as caucasians
2013-12-19
African-American women must eat less or exercise more to lose as much weight as caucasians
PITTSBURGH, Dec. 19, 2013 – African-American women may need to eat fewer calories or burn more than their Caucasian counterparts to ...
Deepwater Horizon NRDA study shows possible oil impact on dolphins
2013-12-19
Deepwater Horizon NRDA study shows possible oil impact on dolphins
Nearly half of Barataria Bay dolphins in 'guarded' condition
VIDEO:
Video shows 2011 Deepwater Horizon ...
A mathematical perspective of seasonal variations in Lyme disease transmission
2013-12-19
A mathematical perspective of seasonal variations in Lyme disease transmission
Philadelphia, PA—Lyme disease is a common tick-borne illness caused by a bacterium, which is transmitted to humans through the bite of infected ticks. ...
Reinterpreting origins, examining skeletal preservation, and understanding volcanics
2013-12-19
Reinterpreting origins, examining skeletal preservation, and understanding volcanics
Boulder, Colo., USA – GSA Bulletin articles posted online ahead of print on 6 and 13 December 2013 cover earthquake hazards of the Santa Barbara suburban area; apatite and the skeletons ...
Suicide is widely deemed immoral because it 'taints the soul,' study shows
2013-12-19
Suicide is widely deemed immoral because it 'taints the soul,' study shows
Findings cross religious and political Lines, psychologists at Boston College and Boston University report
CHESTNUT HILL, Mass. (12-19-13) – Suicide is a major public health issue; it takes the lives of more than ...
Living at home with dementia
2013-12-19
Living at home with dementia
Study reports substantial unmet needs for patients and caregivers alike
Most people with dementia who live at home have multiple unmet health and welfare needs, any number of which could jeopardize their ability to remain home for ...